Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This inhibition stops the synthesis of nucleotides needed for DNA replication, thereby reducing the proliferation of rapidly dividing cells such as immune cells in autoimmune disease and cancer cells in malignancies.

The dose of Methofill is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. No standard dosing regimen is provided here; the prescriber will calculate the appropriate amount for each patient.

Methofill is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause severe fetal malformations or death. It is also not recommended while breastfeeding, as it may be excreted in milk and harm the infant.

To order Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methofill (methotrexate) shares the folate‑antagonist mechanism with other antimetabolites such as pemetrexed, but methotrexate is distinguished by its long‑standing use in both autoimmune diseases and a broad range of cancers. Its dosing flexibility and extensive clinical experience make it a cornerstone therapy, whereas newer agents may target more specific pathways.

Methofill should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keeping the product in its original packaging helps maintain stability and ensures potency until administration.

Methofill is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a short infusion period, with dosing intervals determined by the treating physician based on the underlying condition.

The most serious adverse risks include severe liver toxicity or fibrosis, profound bone‑marrow suppression leading to anemia or infection, and pulmonary complications such as interstitial pneumonitis. Patients should be monitored regularly for signs of these conditions, and therapy should be stopped if they occur.

Methofill is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic impairment, uncontrolled renal dysfunction, or known hypersensitivity to methotrexate. Caution is also advised for patients with pre‑existing lung disease or active infections.